Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Phase I/II study to evaluate pharmacokinetics, pharmacodynamics, safety, and anticancer activity of avelumab in pediatric subjects from birth to less than 18 years of age with refractory or relapsed solid tumors and lymphoma

Trial Profile

Open-label, Phase I/II study to evaluate pharmacokinetics, pharmacodynamics, safety, and anticancer activity of avelumab in pediatric subjects from birth to less than 18 years of age with refractory or relapsed solid tumors and lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs Avelumab (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 10 Apr 2018 Planned End Date changed from 31 Jan 2022 to 9 Jun 2022.
    • 10 Apr 2018 Planned primary completion date changed from 31 Jan 2022 to 2 Jun 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top